Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase<scp>III</scp>trials
Eric L. Simpson(Oregon Health & Science University), Kristian Reich(Dermatologikum Hamburg), Jacob P. Thyssen(Bispebjerg Hospital), Lynda Spelman(Veracity Clinical Research), Amy S. Paller(Northwestern University), Thomas Bieber(CK-CARE), Kenji Kabashima(Kyoto University), Emma Guttman‐Yassky(Icahn School of Medicine at Mount Sinai), Robert Bissonnette(Innovaderm (Canada)), Margaret Gamalo(Eli Lilly (United States)), Amy M. DeLozier(Eli Lilly (United States)), Fabio P. Nunes(Eli Lilly (United States)), Yuichiro Tsunemi(Saitama Medical University), Antonio Costanzo(Humanitas University), J.‐P. Lacour(Centre Hospitalier Universitaire de Nice), Brett King(Yale University), Lawrence F. Eichenfield(University of California San Diego), Ricardo Galimberti(Hospital Italiano de Buenos Aires), Andreas Wollenberg(University Hospital Augsburg), Lisa A. Beck(Newcastle University), Dennis Brinker(Eli Lilly (United States)), T. Cardillo(Eli Lilly (United States)), Jonathan Janes(Eli Lilly (United States)), Jonathan I. Silverberg(George Washington University)
Cited by 377
Related Papers
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report
|Journal of Allergy and Clinical Immunology|2010|2.3k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2k
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
|Frontiers in Oncology|2018|1.3k
Guidelines of care for the management of atopic dermatitis
|Journal of the American Academy of Dermatology|2013|1.3k
Guidelines of care for the management of atopic dermatitis
|Journal of the American Academy of Dermatology|2014|1.2k